RU2019105691A - Биомаркеры для прогнозирования преждевременных родов из-за преждевременного разрыва плодной оболочки при недоношенной беременности и идиопатических самопроизвольных родов - Google Patents

Биомаркеры для прогнозирования преждевременных родов из-за преждевременного разрыва плодной оболочки при недоношенной беременности и идиопатических самопроизвольных родов Download PDF

Info

Publication number
RU2019105691A
RU2019105691A RU2019105691A RU2019105691A RU2019105691A RU 2019105691 A RU2019105691 A RU 2019105691A RU 2019105691 A RU2019105691 A RU 2019105691A RU 2019105691 A RU2019105691 A RU 2019105691A RU 2019105691 A RU2019105691 A RU 2019105691A
Authority
RU
Russia
Prior art keywords
premature
biomarkers
pregnant woman
labor
likelihood
Prior art date
Application number
RU2019105691A
Other languages
English (en)
Russian (ru)
Inventor
Джон Джей БОНИФЕЙС
Джулия БЕРЧАРД
Грег Чарльз КРИЧФИЛД
Трейси Кристин ФЛЯЙШЕР
Дерлин Эдвард ХИКОК
Чиэнь ХСУ
Original Assignee
Сера Прогностикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сера Прогностикс, Инк. filed Critical Сера Прогностикс, Инк.
Publication of RU2019105691A publication Critical patent/RU2019105691A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/10Libraries containing peptides or polypeptides, or derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00Chemical aspects of mass spectrometric analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/368Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
RU2019105691A 2016-08-05 2017-08-04 Биомаркеры для прогнозирования преждевременных родов из-за преждевременного разрыва плодной оболочки при недоношенной беременности и идиопатических самопроизвольных родов RU2019105691A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662371666P 2016-08-05 2016-08-05
US62/371,666 2016-08-05
US201762449862P 2017-01-24 2017-01-24
US62/449,862 2017-01-24
PCT/US2017/045576 WO2018027171A1 (en) 2016-08-05 2017-08-04 Biomarkers for predicting preterm birth due to preterm premature rupture of membranes versus idiopathic spontaneous labor

Publications (1)

Publication Number Publication Date
RU2019105691A true RU2019105691A (ru) 2020-09-08

Family

ID=61073085

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019105691A RU2019105691A (ru) 2016-08-05 2017-08-04 Биомаркеры для прогнозирования преждевременных родов из-за преждевременного разрыва плодной оболочки при недоношенной беременности и идиопатических самопроизвольных родов

Country Status (10)

Country Link
US (3) US20180172698A1 (cg-RX-API-DMAC7.html)
EP (1) EP3494233A4 (cg-RX-API-DMAC7.html)
JP (2) JP2019532261A (cg-RX-API-DMAC7.html)
KR (1) KR20190046825A (cg-RX-API-DMAC7.html)
CN (1) CN110191963A (cg-RX-API-DMAC7.html)
AU (1) AU2017307584A1 (cg-RX-API-DMAC7.html)
CA (1) CA3032754A1 (cg-RX-API-DMAC7.html)
IL (1) IL264576A (cg-RX-API-DMAC7.html)
RU (1) RU2019105691A (cg-RX-API-DMAC7.html)
WO (1) WO2018027171A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2724013C2 (ru) 2015-06-19 2020-06-18 Сера Прогностикс, Инк. Пары биологических маркеров для предсказания преждевременных родов
EP3668996A4 (en) 2017-08-18 2021-04-21 Sera Prognostics, Inc. PREGNANCY CLOCK PROTEIN TO PREDICT THE EXPECTED DATE AND TIME OF BIRTH
JP2021501343A (ja) * 2017-10-30 2021-01-14 カーメンティクス・プロプライエタリー・リミテッド 早産のバイオマーカー
EP4165416A1 (en) * 2020-06-10 2023-04-19 Board of Regents, The University of Texas System Method for determining risk of pre-term birth
US20240013925A1 (en) * 2020-11-05 2024-01-11 Board Of Regents, The University Of Texas System Individual optimal mode of delivery
WO2022246288A2 (en) * 2021-05-21 2022-11-24 Sera Prognostics, Inc. Biomarker pairs and triplets for predicting preterm birth
RU2763707C1 (ru) * 2021-06-01 2021-12-30 Наталья Борисовна Кузнецова Способ прогнозирования преждевременного разрыва плодных оболочек в сроке от 22 до 28 недель беременности
US11664100B2 (en) 2021-08-17 2023-05-30 Birth Model, Inc. Predicting time to vaginal delivery
WO2023102786A1 (zh) * 2021-12-08 2023-06-15 深圳华大基因股份有限公司 基因标志物在预测孕妇早产风险中的应用
WO2024156709A1 (en) * 2023-01-24 2024-08-02 Université Clermont Auvergne Evaluation of serum cx3cl1 for the prediction of preterm premature rupture of membranes
WO2024182491A1 (en) * 2023-02-28 2024-09-06 Virginia Commonwealth University Polygenic risk estimator for cervical length change during pregnancy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233400A1 (en) * 2004-03-03 2005-10-20 Weiner Carl P Proteomic method for predicting success of rescue cerclage
RU2586412C2 (ru) * 2012-06-09 2016-06-10 Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") Способ оценки риска возникновения патологии беременности
US20140186332A1 (en) * 2012-12-28 2014-07-03 NX Pharmagen Biomarkers of preterm birth
WO2014110098A1 (en) * 2013-01-08 2014-07-17 Duke University Biomarkers for the prediction of preterm birth
EP2972393A4 (en) * 2013-03-15 2016-10-26 Sera Prognostics Inc BIOMARKERS AND METHOD FOR PREDICTING PREECLAMPSIA
US20140287948A1 (en) * 2013-03-15 2014-09-25 Sera Prognostics, Inc. Biomarkers and methods for predicting preterm birth
EP3800470A1 (en) * 2013-03-15 2021-04-07 Sera Prognostics, Inc. Biomarkers and methods for predicting preterm birth
RU2724013C2 (ru) * 2015-06-19 2020-06-18 Сера Прогностикс, Инк. Пары биологических маркеров для предсказания преждевременных родов

Also Published As

Publication number Publication date
KR20190046825A (ko) 2019-05-07
EP3494233A4 (en) 2020-03-18
WO2018027171A1 (en) 2018-02-08
CN110191963A (zh) 2019-08-30
IL264576A (en) 2019-02-28
JP2019532261A (ja) 2019-11-07
US20210190792A1 (en) 2021-06-24
CA3032754A1 (en) 2018-02-08
US20250085293A1 (en) 2025-03-13
US20180172698A1 (en) 2018-06-21
EP3494233A1 (en) 2019-06-12
JP2022140511A (ja) 2022-09-26
AU2017307584A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
RU2019105691A (ru) Биомаркеры для прогнозирования преждевременных родов из-за преждевременного разрыва плодной оболочки при недоношенной беременности и идиопатических самопроизвольных родов
JP2019532261A5 (cg-RX-API-DMAC7.html)
ESCP Cohort Studies Sub-Committee et al. Predictors for anastomotic leak, postoperative complications, and mortality after right colectomy for cancer: results from an international snapshot audit
Salamonsen et al. Proteomics of the human endometrium and uterine fluid: a pathway to biomarker discovery
Clausen et al. Noninvasive fetal RhD genotyping
EA201892490A1 (ru) Пцр с мультиплексной оптимизированной амплификацией неправильно спаренных оснований (moma) в реальном времени для анализа состояния плода
Starikov et al. Comparison of placental findings in type 1 and type 2 diabetic pregnancies
Christensen et al. Preeclampsia and cardiovascular disease risk assessment–do arterial stiffness and atherosclerosis uncover increased risk ten years after delivery?
EA202090348A1 (ru) Способ неинвазивного пренатального выявления аномалий половых хромосом у плода и определения пола плода в случае одноплодной и двухплодной беременности
EP4461818A3 (en) Methods for cell-type specific profiling to identify markers for nuclei isolation
EA201792389A1 (ru) Пцр в реальном времени для мультиплексной оптимизированной амплификации с несоответствиями (moma) и для оценки неклеточной днк
EA201892489A1 (ru) Число мишеней для мультиплексной оптимизированной амплификации с несоответствиями (moma)
Buysse et al. Reliable noninvasive prenatal testing by massively parallel sequencing of circulating cell-free DNA from maternal plasma processed up to 24 h after venipuncture
Wolfe et al. Banking placental tissue: an optimized collection procedure for genome-wide analysis of nucleic acids
WO2015136509A3 (en) Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy
EA201792570A1 (ru) Мультиплексный параллельный анализ целевых геномных областей с целью неинвазивного пренатального тестирования
Piotrowski et al. Global cardiovascular mortality risk in the adult Polish population: prospective assessment of the cohorts studied in multicentre national WOBASZ and WOBASZ Senior studies
HK1257122A1 (zh) Lrp5作为用於鉴定免疫细胞特别是b细胞的表观遗传标志物
WO2014153232A3 (en) Methods and compositions for diagnosing preeclampsia
HUE061561T2 (hu) Eljárás és berendezés magzati nukleinsav-koncentráció meghatározására várandós nõ vérében
WO2015173430A3 (en) Early placenta insulin-like peptide (pro-epil)
MX2018010984A (es) Deteccion del tiempo de inseminacion apropiado mediante reconocimiento del patron de marcador de preñez multiple (mpmp).
Brady et al. Maternal serum alpha-fetoprotein levels peak at 19-21 weeks' gestation and subsequently decline in an NPHS1 sequence variant heterozygote; implications for prenatal diagnosis of congenital nephrosis of the Finnish type
Rahman et al. Chlamydia trachomatis IgM seropositivity during pregnancy and assessment of its risk factors
Pillay et al. Why are we still measuring red cell folate instead of just serum folate?

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20200805